Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Anchored Transponder Guided Lung Radiation TherapyPractical Radiation Oncology.  10:e37-e44. 2020
2020 Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancerSupportive Care in Cancer2020
2019 Electromagnetic Transponder Based Tracking and Gating in the Radiotherapeutic Treatment of Thoracic MalignanciesPractical Radiation Oncology.  9:456-464. 2019
2019 Feasibility of Dose Escalating [18F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate CancerAdvances in Radiation Oncology.  4:649-658. 2019
2019 Longitudinal assessment of anchored transponder migration following lung stereotactic body radiation therapyJournal of Applied Clinical Medical Physics.  20:17-22. 2019
2019 Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines 2019
2019 Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective TrialAdvances in Radiation Oncology.  4:90-95. 2019
2018 NCCN guidelines® insights: Small cell lung cancer, version 2.2018 featured updates to the NCCN guidelines 2018
2018 NCCN guidelines ® insights non–small cell lung cancer, version 5.2018 featured updates to the NCCN guidelines 2018
2018 Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy with 212 Pb-TCMC-Trastuzumab 2018
2018 Stereotactic Radiosurgery for Prostate Cancer Following Magnetic Resonance Imaging Directed Biopsy: A Multidisciplinary Approach with Case Examples.Cureus.  10:e2524. 2018
2017 Subcutaneous adipose tissue characteristics and the risk of biochemical recurrence in men with high-risk prostate cancerUrologic Oncology: Seminars and Original Investigations.  35:663.e15-663.e21. 2017
2017 Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology 2017
2017 Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: A secondary analysis of the NRG oncology RTOG 0617 randomized clinical trialJournal of Clinical Oncology.  35:56-62. 2017
2016 Analysis of Predictive Factors for Acute Esophagitis in Lung Cancer Radiation Therapy. 2016
2016 Analysis of Predictive Factors for Pneumonitis in Lung Cancer Radiation Therapy. 2016
2016 Correction: Kinomic profiling of electromagnetic navigational bronchoscopy specimens: A new approach for personalized medicine (PLoS ONE (2016) 9:12 (e116388) DOI: 10.1371/journal.pone.0116388)PLoS ONE.  11. 2016
2016 NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016 2016
2016 NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines 2016
2016 Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined-modality therapy for muscle-invasive bladder cancer: A pooled analysis of NRG Oncology/RTOG 9906 and 0233 2016
2015 Non-Small Cell Lung Cancer, Version 6.2015. 2015
2015 Non-Small cell lung cancer, version 6.2015: Featured updates to the NCCN guidelines 2015
2015 A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: Final results of radiation therapy oncology group phase 3 randomized trial NRG oncology RTOG 9902 2015
2015 Continuous chemoradiation following complete response to neo-adjuvant chemotherapy provides improved outcomes in muscle invasive urothelial carcinomaJournal of Solid Tumors.  5:59-68. 2015
2015 Retention rate of electromagnetic navigation bronchoscopic placed fiducial markers for lung radiosurgeryAnnals of Thoracic Surgery.  100:1163-1166. 2015
2014 Kinomic profiling of electromagnetic navigational bronchoscopy specimens: A new approach for personalized medicinePLoS ONE.  9. 2014
2014 Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomideRadiation Oncology.  9. 2014
2014 Comparison of plan quality and delivery time between volumetric arc therapy (rapidarc) and gamma knife radiosurgery for multiple cranial metastasesNeurosurgery.  75:409-417. 2014
2014 PSA response to neoadjuvant androgen deprivation is an independent prognostic marker and may identify patients who benefit from treatment escalationUrologic Oncology: Seminars and Original Investigations.  32:687-693. 2014
2013 Effects of flattening filter-free and volumetric-modulated arc therapy delivery on treatment efficiency.Journal of Applied Clinical Medical Physics.  14:4328. 2013
2013 Stereotactic body radiation therapy (SBRT) for lung malignancies: Preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minuteRadiation Oncology.  8. 2013
2013 Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofractionated simultaneous versus conventionally fractionated sequential boost for patients with high-risk prostate cancerActa Oncologica.  52:1181-1188. 2013
2013 Patient benefit from salvage radiation for prostate cancer.Journal of Clinical Oncology.  31:175. 2013
2013 Effects of flattening filter-free and volumetric-modulated arc therapy delivery on treatment efficiencyJournal of Applied Clinical Medical Physics.  14:155-166. 2013
2013 Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapyJournal of Applied Clinical Medical Physics.  14:4126. 2013
2013 Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapyJournal of Applied Clinical Medical Physics.  14:64-71. 2013
2013 Optimal planning target volume margins for elective pelvic lymphatic radiotherapy in high-risk prostate cancer patients.ISRN Oncology.  2013:941269. 2013
2012 Hypofractionated Prostate Radiotherapy with or without Conventionally Fractionated Nodal Irradiation: Clinical Toxicity Observations and Retrospective Daily Dosimetry.Prostate Cancer.  2012:546794. 2012
2011 Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiationRadiotherapy and Oncology.  101:183-189. 2011
2011 Cetuximab augments cytotoxicity with poly (ADP-Ribose) polymerase inhibition in head and neck cancerPLoS ONE.  6. 2011
2011 Efficacy and rectal toxicity of hypofractionated radiation therapy with daily image guidance.Journal of Clinical Oncology.  29:85. 2011
2011 Dosimetric analysis of imaging changes following pulmonary stereotactic body radiation therapy 2011
2011 Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide 2011
2010 Margin on Gross Tumor Volume and Risk of Local Recurrence in Head-and-Neck Cancer 2010
2009 Cancer of the tonsil presenting as central nervous system metastasis: A case report 2009
2006 Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: A phase I study 2006

Principal Investigator On

  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2014 - 2017
  • Private Grant  awarded by COVIDIEN 2014 - 2015
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2009 - 2011
  • Investigator On

  • Private Grant  awarded by ELI LILLY AND COMPANY 2019 - 2026
  • Private Grant  awarded by ELI LILLY AND COMPANY 2019 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019 - 2024
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2019 - 2023
  • A Phase II Study of Durvalumab (MEDI 4736) with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma  awarded by University of North Carolina at Chapel Hill 2020 - 2023
  • Private Grant  awarded by ELI LILLY AND COMPANY 2020 - 2023
  • RTOG Foundation Master Service Agreement for Participation in Foundation Research: RTOG 3501 Tryhard: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer with Concurrent Chemoradiation  awarded by American College of Radiology 2012 - 2022
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2019 - 2022
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2015 - 2021
  • A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer  awarded by University of Florida 2020 - 2021
  • Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial  awarded by University of Pennsylvania 2019 - 2020
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Private Grant  awarded by NOVOCURE, INC. 2017 - 2019
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2018
  • Private Grant  awarded by SUCAMPO PHARMACEUTICALS 2016
  • Private Grant  awarded by SPECTRUM PHARMACEUTICALS, INC. 2013 - 2016
  • Private Grant  awarded by ELI LILLY AND COMPANY 2012 - 2015
  • Private Grant  awarded by ABBOTT LABORATORIES 2012 - 2014
  • Education And Training

  • Doctor of Medicine, Medical College of Ohio 2002
  • Mercy St. Vincent Medical Center, Internship 2003
  • UAB Hospital, Residency 2007
  • Full Name

  • Michael Dobelbower